Celgene Psoriasis Drug Meets Midstage Study Goal
From Associated Press (December 15, 2009)
SUMMIT, N.J.--Biotechnology company Celgene Corp. said Tuesday its experimental psoriasis treatment, apremilast, met key goals in a midstage clinical trial.
The company said apremilast reduced the severity of moderate-to-severe psoriasis during the study. Specifically, 41 percent of patients receiving the 30-milligram dose met treatment goals, compared with only 6 percent taking placebo.
Psoriasis is a chronic inflammatory skin condition, with symptoms including redness and irritation.
Celgene said results from the study support a move to advance the drug candidate to late-stage development in 2010.
Shares of Celgene fell 41 cents to $53.47 in midday
trading.
Posted: December 2009
